Showing 653 results
- Media Release /-- At six months, adjusted mean treatment satisfaction scores increased by a statistically significant 20.4 with Gilenya vs. 2.9 with injectable disease modifying therapies1-- In one of the largest…
- Media Release /
- Media Release /- Latest Phase III research on Afinitor® in advanced HER2 positive breast cancer- Jakavi™ overall survival advantage evaluated in three-year study in patients with myelofibrosis, a rare and life-…
- Media Release /
- Media Release /- Discounts and rebates by pharmaceutical companies are a customary, appropriate and legal practice as recognized by the Government- Physician speaker programs are also an accepted practice designed…
- Media Release /
- Media Release /- TOBI Podhaler is portable and requires no nebulizer, refrigeration or power source to deliver the medicine- TOBI Podhaler is indicated for certain cystic fibrosis (CF) patients with Pa and shortens…
- Media Release /
- Media Release /-- Data show reductions in rate of brain volume loss by about one-third compared to interferon beta-1a IM or placebo in studies with over 3,600 patients with relapsing MS1-- Gilenya is the first oral…
- Media Release /
Pagination
- ‹ Previous page
- 1
- …
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- …
- 66
- › Next page